<DOC>
	<DOC>NCT00471159</DOC>
	<brief_summary>To assess the efficacy and safety of PF-3512676 administered in combination with docetaxel for the treatment of patients with advanced breast cancer.</brief_summary>
	<brief_title>A Study Of Docetaxel Or Docetaxel Plus PF-3512676 To Treat Patients With Advanced Breast Cancer.</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>Female patients with confirmed advanced breast cancer. Patients with HER2 negative disease with documented disease progression after (neo)adjuvant treatment with an anthracyclinebased chemotherapy regimen. Patients with adequate general wellbeing, kidney and liver function. Patients that have any condition that could affect patients safety, interfere with trial results, or makes the patient inappropriate for inclusion into study. Patients who have had prior chemotherapy for advanced breast cancer. Patients of childbearing potential who are unwilling to use contraception.</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>